The UK remains a globally significant market, characterised by strong financial services, advanced technology hubs, and a dynamic consumer economy.

The pharmaceutical industry is experiencing structural transformation. Biologics and biosimilars are capturing increasing market share, while small molecule drugs, once

Canada offers a stable, resource-rich, and innovation-oriented market, shaped by a bilingual and multicultural society. Economic resilience is underpinned by

B2B markets differ from consumer markets in their lengthier sales cycles, multi-stakeholder decision-making, and heightened emphasis on return on investment.